Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib plus rituximab-bendamustine in relapsed/refractory diffuse large B-cell lymphoma
2019-004898-63Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of copanlisib, rituximab and bendamustine in diffuse large B-cell lymphoma (DLBCL), transformed large B-cell lymphoma (tDLBCL) and high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Progression-free survival. Started Oct 2020; status: completed.
02
Drugs
copanlisibrituximabbendamustine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)transformed large B-cell lymphoma (tDLBCL)high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH)
Beyond the preview
Go deeper on 2019-004898-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004898-63.